drug · oligonucleotide
Hypertriglyceridemia
pre_registrationupdated 6mo agoby LP Pharmaceutical (Xiamen) Co Ltd🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 6Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
targets
Apolipoprotein C-III mRNA 3'UTR
all catalysts(0)
nothing on the calendar yet
News(10)
- Cellectis could cut 70% of workforce in shift to in vivo therapiesCellectis’ business transformation could cost around 160 global employees their jobs. The company has stopped enrollment in its two CAR T programs as it focuses on trials of its in vivo candidates.biospace · 3d ago
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 3d ago
- Cellectis will shed 70% of workforce as part of in vivo pivotCellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.fiercebiotech · 4d ago
- #AHA26: Marea’s triglyceride candidate could have an edge in diabetic patientsMarea Therapeutics' investigational lipid-lowering medicine has shown further promise in cutting triglycerides in patients with dangerously high levels of these fatty molecules in their blood. It a…endpoints · 7d ago
- Recent Lisata prize Marea touts ‘exciting’ lipid disorder phase 2 win, mulls obesity potentialFresh from a merger with oncology drugmaker Lisata Therapeutics, cardiometabolic biotech Marea Therapeutics has revealed results from the first part of a phase 2b study showing its drug candidate M…fiercebiotech · 11d ago
- GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatmentHibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug ap…biospace · 26d ago
- On the move: 4 rare disease companies hiring nowBiotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.biospace · 1mo ago
- Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodA late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay…biospace · 1mo ago
- Lisata deal propels Marea’s drug pipeline to Wall StreetMarea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.biopharma_dive · 2mo ago
- After one failed acquisition attempt, Lisata finds lifeline in Marea mergerAfter a failed merger that led to massive layoffs and a lawsuit, solid tumor biotech Lisata Therapeutics has found a new future through a merger with cardio specialist Marea Therapeutics.fiercebiotech · 2mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that